The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in ...

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration. Itvisma, or onasemnogene abeparvovec-brve, was approved ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Mary is the bedrock of her family. “She’s the one we all go to,” says her son Eric. “She’s selfless, extremely sweet, very personable—but she can also be very feisty.” So when she returned from an eye ...

The earlier patients with potentially blinding geographic atrophy start treatment with the complement inhibitor pegcetacoplan, the more retinal tissue they retain 4 years later compared with patients ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Learning how to diffuse curly hair is a part of any curly girl’s beauty journey. After all, making sure you’re properly drying your waves and coils while minimizing heat damage is key to healthy, ...

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in presymptomatic ...

Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with ...

Spinal muscular atrophy with respiratory distress (SMARD) is a rare genetic condition that typically affects infants and children. It causes muscle weakness and breathing problems. Spinal muscular ...